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ABSTRACT  36	
Context: While both overt hyper- and hypothyroidism are known to lead to cognitive impairment, data on 37	
the association between subclinical thyroid dysfunction and cognitive function are conflicting.  38	
Objective: To determine the risk of dementia and cognitive decline associated with subclinical thyroid dys-39	
function among prospective cohorts. 40	
Data Sources: Search in MEDLINE, EMBASE until November 2014. 41	
Study Selection: Two physicians identified prospective cohorts that assessed thyroid function and cognitive 42	
outcomes (dementia; Mini-Mental State Examination, MMSE). 43	
Data Extraction: Data were extracted by one reviewer following standardized protocols and verified by a 44	
second reviewer. The primary outcome was dementia and decline in cognitive function was the secondary 45	
outcome.  46	
Data Synthesis: Eleven prospective cohorts followed 16,805 participants during a median follow-up of 47	
44.4 months. Five studies analyzed the risk of dementia in subclinical hyperthyroidism (n=6410), six in 48	
subclinical hypothyroidism (n=7401). Five studies analyzed MMSE decline in subclinical hyperthyroidism 49	
(n=7895), seven in subclinical hypothyroidism (n=8960). In random-effects models, the pooled adjusted RR 50	
for dementia in subclinical hyperthyroidism was 1.67 (95% confidence interval [CI] 1.04-2.69) and 1.14 51	
(95%CI 0.84-1.55) in subclinical hypothyroidism versus euthyroidism, both without evidence of significant 52	
heterogeneity (I2=0.0%). The pooled mean MMSE decline from baseline to follow-up (mean 32 months) 53	
did not significantly differ between subclinical hyper- or hypothyroidism versus euthyroidism.  54	
Conclusions: Subclinical hyperthyroidism might be associated with an elevated risk for dementia, while 55	
subclinical hypothyroidism is not, and both conditions are not associated with faster decline in MMSE over 56	
time. Available data are limited, and additional large, high-quality studies are needed.  57	
  58	
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CONTEXT 59	
The prevalence of subclinical hypothyroidism (SHypo) reaches up to 10% in the elderly population, while 60	
subclinical hyperthyroidism (SHyper) has a prevalence of 2.4%, and 4.3% in the population aged ≥80 61	
years.1,2 SHypo is biochemically defined as elevated serum thyroid-stimulating hormone (TSH, thyrotropin) 62	
levels, but free thyroxin (fT4) levels within laboratory reference ranges3, SHyper is defined as decreased 63	
serum TSH concentrations and normal fT4 and fT3 levels. The subclinical forms of thyroid dysfunction have 64	
previously been associated with increased risk of heart failure and coronary heart disease.4-6 Furthermore, 65	
SHyper may negatively influence bone and mineral metabolism.7  66	
While both overt hyper- and hypothyroidism are known to lead to cognitive impairment and clinical guide-67	
lines recommend screening for thyroid dysfunction among patients with cognitive disorders8, data on the 68	
association between subclinical thyroid dysfunction (SCTD) and cognitive function remained conflicting. In 69	
the general population, the prevalence of mild cognitive impairment is 3-22%, with a higher prevalence 70	
among adults >70 years (14-18%).9-11 Mild cognitive impairment, a cognitive decline not normal for age but 71	
with essentially preserved functional activities, is believed to be the earliest clinical symptom of cognitive 72	
disorders and may be the stage to intervene with preventive therapies.11,12 The progression rate from cogni-73	
tive impairment to dementia in the general population aged > 65 years is around 6-10% per year.11 SHyper 74	
has also been associated with increased risk of dementia, 13 with one retrospective cohort reporting a hazard 75	
ratio of 1.6 (95% confidence interval [CI] 1.2-2.3) for dementia.14 SHypo might also be associated with 76	
alterations in cognitive function,13,15,16 with one case-control study reporting a nearly 4-fold increase in the 77	
odds ratio of dementia (OR=3.8, 95%CI 1.6-9.1).17  78	
However, data on the association between SCTD and cognitive function are conflicting.18-20  79	
Two recent meta-analyses yielded discrepant findings for SHypo, one showing a significant risk of cogni-80	
tive alteration (composite endpoint of reduced Mini-Mental State Examination (MMSE), Wechsler Memory 81	
Scale-Revised, total memory quotient and Wechsler Adult Intelligence Scale scores) for SHypo individuals 82	
younger than 75 years with an OR of 1.56 (95%CI 1.07-2.27),21 whereas the other found no decline in 83	
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MMSE in SHypo patients aged ≥60 years (pooled estimate [ES] 0.03, 95%CI −0.001–0.07).22 As both me-84	
ta-analyses were limited by pooling heterogeneous study designs (prospective and retrospective data), and 85	
did neither examine the risk of dementia nor cognitive function associated with SHyper, we conducted a 86	
meta-analysis to determine whether SHyper and SHypo were associated with an increased risk of dementia 87	
or decline in cognitive function in prospective cohorts, the gold standard for observational data.  88	
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METHODS 89	
Data sources and Searches 90	
To perform this systematic review, we followed a pre-defined protocol registered on PROSPERO (Record: 91	
CRD42015019819). We conducted a systematic literature search in MEDLINE and EMBASE databases 92	
from inception until November 2014 searching for articles related to SCTD and cognitive decline and de-93	
mentia. The Medical Subject Headings (Mesh) in Ovid MEDLINE included “thyroid disease”, “hypothy-94	
roidism”, “hyperthyroidism”, “thyroid hormones”, “thyrotropin”, “subclinical hyperthyroidism”, “subclini-95	
cal hypothyroidism”, “subclinical dysthyroidism”, “subclinical thyroid”, “cognition”, “dementia”, 96	
“memory”, “Alzheimer”, “cognitive”, “cohort studies”, “cohort”, “controlled clinical trial”, “epidemiologic 97	
methods”, “review”. We applied a cohort filter designed by the British Medical Journal knowledge infor-98	
mation specialists23 but did not use any other filters or restrictions including year limitations or language 99	
restrictions. A similar strategy with similar terms was used for EMBASE. Additionally, we searched the 100	
bibliographies of included articles, as well as key articles in the field, and contacted several authors for un-101	
published subgroup data. 102	
 103	
Study Selection (Figure 1) 104	
Two reviewers (CR, DS) independently screened titles and abstracts of the search results and selected pub-105	
lications. In a second step, the same two reviewers independently evaluated the full-text publications of the 106	
retrieved studies according to the following pre-specified eligibility criteria: prospective cohort studies 107	
among participants ≥18 years, including a SCTD and a euthyroid control group with thyroid function tests 108	
at baseline and assessment of cognitive function during follow-up, with published risk estimates or suffi-109	
cient information to calculate them. We excluded studies examining solely participants with overt thyroid 110	
disease. Disagreements were resolved by an independent third author (NR). SHyper was defined as de-111	
creased or undetectable TSH and normal fT4, and SHypo as elevated TSH and normal fT4. Cohort-specific 112	
TSH- and fT4-cutoff levels were used to determine thyroid status. For dementia definition, we accepted all 113	
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validated assessments of memory and cognitive function, and did not exclude studies that reported other 114	
scales than MMSE. For our analyses, we also collected information on clinical dementia (Supplement ta-115	
ble 1). Additionally, we gathered data on MMSE results at baseline and follow-up visits. Studies were in-116	
cluded if they provided information on either dementia or MMSE outcomes, or both. 117	
 118	
Data Extraction and Quality Assessment 119	
Standardized data extraction forms were used to collect information from the included cohorts concerning 120	
patient characteristics, thyroid hormone levels, and scales for tests or criteria used to define memory func-121	
tion, dementia or Alzheimer’s disease (AD). Data were extracted by one reviewer (CR) and verified by a 122	
second independent reviewer (DS). Discrepancies were solved by a third author (NR). Two reviewers (CR, 123	
DS) independently assessed study quality using key indicators of cohort study quality24,25: origin of popula-124	
tion (convenience versus population-based, the latter defined as a random sample of the general population), 125	
methods of outcome ascertainment and adjudication (considered as adequate if in each potential case per-126	
formed by an expert panel blinded regarding the thyroid status and following defined outcome criteria), 127	
completeness of follow-up, assessment of the proportional hazard assumption and adjustment for confound-128	
ers.  129	
 130	
Data Synthesis and Statistical Analysis 131	
We performed four main analyses on the association of 1) subclinical hyperthyroidism and dementia, 2) 132	
subclinical hypothyroidism and dementia, 3) subclinical hyperthyroidism and MMSE and 4) subclinical 133	
hypothyroidism and MMSE. We expressed the estimates of the association between SCTD (i.e. SHyper or 134	
SHypo) and outcomes as risk ratios (RR) for dementia or as between-group differences in mean changes 135	
from baseline for MMSE scores (MD). Only prospective data were analyzed. A RR>1 indicates a higher 136	
risk of an event in SCTD compared to euthyroids and a MD>0 indicates higher decline of MMSE in SCTD 137	
compared to euthyroids. To account for the different lengths of follow-up time across studies, we standard-138	
ized MD per 1 year unit. We used most adjusted estimates provided by the studies as primary analysis. We 139	
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used an inverse variance random-effects meta-analysis to pool estimates across studies. Estimates of the 140	
association between SCTD and dementia were pooled on a log scale and latter exponentiated to be reported 141	
as RR. To evaluate heterogeneity across the studies, we used the Q statistic with a conservative p-value of 142	
0.10.26 Furthermore, we calculated the I2 statistic, indicating the proportion of variability in estimates of 143	
effects across studies that is not due to chance alone (<25% low, 25-75% increasing, >75% high heteroge-144	
neity between studies).24 We visually evaluated publication bias through funnel plots and, statistically, with 145	
the Egger’s test.27,28 To explore the sources of heterogeneity, we conducted several sensitivity analyses. Due 146	
to the small number of studies in each group, subgroup analysis with interaction tests could not be meaning-147	
fully performed. All P-values were two-sided. All analyses were conducted using STATA software, version 148	
13.1 (College Station, Texas).   149	
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RESULTS 150	
Study Selection  151	
Of the 1505 reports initially identified, 1471 remained after removing duplicates. We excluded 1435 records 152	
on the basis of their abstracts and 25 after full text examination (Figure 1). Eleven studies met pre-specified 153	
eligibility criteria and were included in the analyses. Among those, 3 studies provided information on both 154	
dementia and MMSE outcomes (Supplement Table 1, Section A), 4 studies reported information on de-155	
mentia outcomes only (Supplement Table 1, Section B), and 4 assessed MMSE outcomes only (Supple-156	
ment Table 1, Section C). The agreement among the reviewers was 98.63% for the first screen of abstracts 157	
(κ=0.75) and 89.74% for the full-text search (κ=0.71). 158	
 159	
Study Characteristics 160	
Eleven cohorts reported data on 16,805 participants (Table 1). Two cohorts only included men.29,30 Mean 161	
age was 70 years or higher, except for one study.31 The follow-up time ranged from 12 to 152 months (me-162	
dian follow-up 44.4 months). Eight cohorts excluded participants treated with thyroid hormones or medica-163	
tions altering thyroid hormone levels, while three excluded the participants taking thyroid hormones or thy-164	
roid altering medication in sensitivity analysis.32-34  165	
 166	
Description and Quality of Studies  167	
The quality of studies was heterogeneous. Nine cohorts were population-based and two were convenience 168	
samples (Supplement Table 1). All the cohorts used third generation TSH assays, except one using second 169	
generation tests and one that did not report test details.35,36 Four studies had a formal adjudication committee 170	
for dementia diagnosis.29-32 Seven studies provided information on attrition during follow-up.20,29,30,32,33,36,37 171	
Six studies provided information on non-violation of the proportional hazard assumption.29,30,33,34,37,38 All 172	
studies reported adjusted data with various confounders, except one study that provided us unadjusted 173	
data.32 174	
 175	
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Subclinical Hyperthyroidism and Dementia  176	
Among five cohorts analyzing the association between SHyper and dementia (n=6410, 329 cases of demen-177	
tia, mean follow-up 68.3 months),29-31,37,38 the pooled risk ratio [RR] of dementia was 1.67 (95%CI 1.04-178	
2.69, I2=0.0%, p for heterogeneity=0.82) among SHyper patients compared with euthyroidism (Figure 2). 179	
Sensitivity analyses (Table 2) excluding one study with a convenience-based sample, one study that fol-180	
lowed both patients with and without thyroid hormone replacement, or studies without or not reported for-181	
mal adjudication for dementia, yielded similar results. As the Framingham study only analyzed the relation-182	
ship with dementia using TSH tertiles (highest tertile: TSH 1.9-9.9 mU/L) and did not measure fT4,34 we 183	
added this study in a sensitivity analysis and found comparable results. A sensitivity analysis excluding 475 184	
overlapping patients between two cohorts31,38 yielded similar results; we did not include these data in the 185	
main analysis, as they examined different follow-up duration and were not based on peer-reviewed pub-186	
lished results (the investigators sent us these data separately). The relationship between SHyper and AD was 187	
assessed by three studies only (n=3186, 108 AD cases, mean follow-up 75.0 months).30,31,38 The pooled RR 188	
for AD was 1.67 (95%CI 0.79-3.51, I2=16.8%, p for heterogeneity=0.30).  189	
 190	
Subclinical Hypothyroidism and Dementia  191	
Among six studies analyzing the relationship between SHypo and dementia (n=7401, 416 cases of demen-192	
tia, mean follow-up 64.6 months),29-32,37,38 the pooled RR for dementia was 1.14 (95%CI 0.84-1.55, 193	
I2=0.0%, p for heterogeneity=0.49) (Figure 2). No individual study showed a statistically significant asso-194	
ciation. Sensitivity analyses (Table 2) excluding a study with a convenience-based sample, studies with 195	
TSH cut-off <4.5mU/l and potentially including individuals in the euthyroid range, two studies that fol-196	
lowed both patients with and without thyroid hormone replacement, studies without or not reported formal 197	
adjudication process for dementia, one study with additional unadjusted data, or 475 overlapping partici-198	
pants between two cohorts31,38 yielded similar results. The addition of the Framingham study34 to the main 199	
analysis yielded similar results. Four studies analyzed the relationship between SHypo and AD (n=3823, 200	
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151 AD cases, mean follow-up 69.36 months).30-32,38 The pooled RR for AD was 0.95 (95%CI 0.52-1.71, 201	
I2=0.0%, p for heterogeneity=0.89). 202	
 203	
Subclinical Hyperthyroidism and MMSE  204	
Among five studies reporting change in MMSE among participants with SHyper (n=7895, mean follow-up 205	
33.6 months),20,31,33,36,37 the pooled mean MMSE decline in cognitive function per year was 0.01 points dif-206	
ference from baseline (95%CI -0.14-0.15; I2=23.5%, p for heterogeneity=0.27; Supplement Figure 1). 207	
Results remained similar after excluding one study using a convenience-based sample or one study that 208	
followed both patients with and without thyroid hormone replacement (Supplement Table 2). Because the 209	
results of the main analyses between SHyper and dementia did not seem concordant with the results of the 210	
meta-analysis looking at the decrease of MMSE in SHyper participants, we undertook a sensitivity analysis 211	
including the two studies examining the relationship of SHyper and both MMSE and dementia31,37, which 212	
also showed no larger decline of MMSE among SHyper. 213	
 214	
Subclinical Hypothyroidism and MMSE  215	
Among seven studies reporting change in MMSE in SHypo (n=8960; mean follow-up 32.2 months),20,31-216	
33,35-37 pooled mean MMSE per year declines did not significantly differ between SHypo and euthyroid 217	
groups (ES 0.01 points difference from baseline, 95%CI -0.10-0.12, I2=27.6%, p for heterogeneity=0.22; 218	
Supplement Figure 1). Sensitivity analyses (Supplement Table 2) excluding one study with a conven-219	
ience-based sample, studies using TSH cut-offs <4.5mU/l, one study that followed both patients with and 220	
without thyroid hormone replacement, one study that might have subclinical hyperthyroid participants in the 221	
control group,35 or one study using unadjusted data yielded similar results. 222	
 223	
Publication bias 224	
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Both graphical inspection and Egger’s tests indicated little evidence of publication bias for all associations, 225	
although the number of available studies was small (Supplement Figure 2).39  226	
  227	
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DISCUSSION AND CONCLUSION  228	
In this meta-analysis of 11 prospective cohorts, we found that SHyper, but not SHypo, might be associated 229	
with an elevated risk for dementia, while decline in MMSE over time was minimal for both conditions. 230	
SHyper showed also a similar pattern of higher risk for AD. Results for the association between SHyper and 231	
dementia remained similar when we pooled higher quality studies in sensitivity analysis, such as studies 232	
with formal adjudication process for the outcome assessment or population-based studies. 233	
Our results for SHyper and risk for dementia are consistent with a non-systematic literature review summa-234	
rizing results from 13 cross-sectional or case-control, and 10 cohort studies that found supportive evidence 235	
of an association between SHyper and cognitive impairment or dementia.40 Of these 10 cohort studies, four 236	
did not meet the eligibility criteria for our systematic review: one due to missing subgroups of thyroid dys-237	
function41, two analyzed only euthyroid participants42,43 and one had a retrospective design14. Several other 238	
individual studies reported an association between SHyper and an elevated risk for dementia as well14,44,45: a 239	
retrospective nested case-control study including 2004 patients with SHyper reported a hazard ratio for de-240	
mentia of 1.79 (95%CI 1.28-2.51), and a cross-sectional study found a positive association between SHyper 241	
and dementia in 1276 participants (33 with SHyper) aged >65 years (OR for dementia 4.1, 95%CI 1.3-242	
13.1).14,44 Van Osch et al prospectively studied 178 patients with AD and 291 community-dwelling controls 243	
without objective cognitive impairment, and found an adjusted OR for AD of 2.36 (95%CI 1.19-4.67) in 244	
participants in the lowest (TSH<1.3mU/l) versus highest TSH tertile (TSH>2.1mU/l).45 Another population-245	
based prospective cohort of 313 elderly adults with normal TSH that found that those with a decline of cog-246	
nitive dysfunction had a mean TSH of 1.78mU/l, while those without decline had a mean TSH of 2.24mU/l 247	
(p=0.001).46  248	
 249	
Our findings might be consistent with the hypothesis that SHyper increases the risk of dementia, although 250	
decline in MMSE over time did not differ between SHyper and euthyroidism. In our meta-analysis, only 251	
two out of 11 studies published results on both dementia and MMSE in SHyper. Analyzing only these two 252	
studies showed no larger decline of MMSE among participants with SHyper. This discrepancy might be 253	
	 	 13	 	 	
	
	
explained by several factors: the length of follow-up of studies on SCTD and dementia was twice the dura-254	
tion of studies on SCTD and MMSE (mean follow-up time 66 vs. 33 months), different population investi-255	
gated, the modest sensitivity of MMSE as a diagnostic tool (79%)47,48, as well as for detecting mild cogni-256	
tive impairment and subtle changes in specific cognitive domains, and the multimodal approach needed to 257	
diagnose dementia.49 Furthermore, different scores were used as gold standard depending on the type and 258	
version of diagnostic criteria (supplement table 1). Factors increasing the plausibility of the association 259	
between SHyper and dementia were that results remained similar when we pooled higher quality studies in 260	
sensitivity analysis, such as studies with formal adjudication process for the outcome assessment or popula-261	
tion-based studies, and that SHyper also showed a pattern of higher risk for AD. However, higher quality 262	
studies are needed. 263	
 264	
Several pathways could explain the association of thyroid dysfunction with cognition and dementia. Thy-265	
roid hormone has distinct effects on the cardiovascular system and thyroid dysfunction has been associated 266	
with several cardiovascular risk factors, including hypertension, dyslipidemia and atrial fibrillation.4,6 In 267	
turn, these cardiovascular risk factors are associated with a higher risk of dementia and Alzheimer’s Dis-268	
ease.50 Most studies included in our meta-analysis adjusted for cardiovascular risk factors. However, the 269	
number and type of variables that were adjusted for differed for each study. Other explanations for the asso-270	
ciation include direct effects of thyroid hormone, such as neurotoxicity and altered gene expression in 271	
pathways relevant for dementia. The exact pathophysiological link between thyroid dysfunction and demen-272	
tia remains unclear and requires more research.  273	
 274	
Recently, two meta analyses on SHypo and cognitive impairment were published, yielding discrepant re-275	
sults.21,22 The first review included 13 studies and found a significant higher risk for cognitive alteration 276	
(composite endpoint of incidence or prevalence of dementia or difference in MMSE, Wechsler Adult Intel-277	
ligence scale and Wechsler Memory-Revised score) in SHypo individuals younger than 75 years (OR 1.56; 278	
95%CI 1.07-2.27, p=0.02), and for dementia (OR 1.81; 95%CI 1.43-2.28, p<0.01).21 However, the authors 279	
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pooled different designs (cross sectional, case-control, cohort studies), used a composite endpoint of clinical 280	
events and scales as primary outcome, and found a significant risk for the primary endpoint only in subclin-281	
ical hypothyroid individuals younger than 75 years. As results were calculated on the basis of mean age, 282	
without availability of individual patient data, they may have been subject to potential aggregation bias 283	
(ecological fallacy).24,51 Contrary to that meta-analysis, all studies in our meta-analysis but one (included 284	
only in a sensitivity analysis) measured fT4 to define SCTD. The second meta-analysis analyzed 15 studies 285	
(9 cross-sectional, 6 prospective cohort studies) and found no association between SHypo and decline in 286	
cognitive function among people aged > 60 years (cross-sectional analysis: pooled ES for MMSE −0.01 287	
points difference from baseline [95%CI −0.09-0.08]; prospective analysis, pooled MMSE change: 0.03 288	
[95%CI −0.001-0.07] p=0.055, with heterogeneity [I2] of <0.001%),22 which is consistent with our findings. 289	
In comparison to these two meta-analyses, we included only prospective cohorts (n=11) allowing us to re-290	
duce the bias that could arise due to differing study designs. To make literature search broad enough, we 291	
excluded studies examining solely participants with overt thyroid disease but added no other exclusion cri-292	
teria. 293	
Two small placebo controlled trials (n=89; n=94) found no evidence that treatment of SHypo with levothy-294	
roxine was associated with improved cognitive function.18,52 However, these trials had several limitations. 295	
In the trial by Parle et al,52 recruitment was based on a single thyroid function test, so that euthyroid partici-296	
pants with transiently elevated TSH may have been included (50% in the placebo group were euthyroid at 297	
12 months), which may have underpowered the trial to detect an effect of hormone replacement.52 Thyroxin 298	
substitution lasted only for 12-months, which may have been too short to affect cognitive function. In the 299	
trial by Jorde et al,18 one third of participants did not attend follow-up. Because of numerous exclusion cri-300	
teria, the study population was unusually healthy, with 57% of the participants having a TSH value between 301	
3.50 and 4.99mU/l, so that it probably included many euthyroid participants. The ongoing TRUST (Thyroid 302	
Hormone Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) may clar-303	
ify whether treatment with levothyroxine in SHypo is associated with better cognitive outcomes over time.53 304	
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There are several strengths of our meta-analysis. By combining the results of 11 prospective cohorts, we 305	
analyzed a total of 432 cases of dementia and 160 cases of AD in more than 15,000 participants. By con-306	
tacting several authors of these studies, we obtained additional data that allowed us to derive more uniform 307	
subgroup and sensitivity analyses. In comparison to the two other meta-analyses,21,22 our results are less 308	
prone to bias due to pooling of heterogeneous study design and quality, because we only included prospec-309	
tive cohorts. We also conducted a detailed literature search in several electronic databases with as few limi-310	
tations as possible in order to retrieve the maximum number of studies available on the topic, and were able 311	
to include a larger number of prospective cohorts than previous meta-analyses.21,22  312	
 313	
Our meta-analysis has also several limitations. Except for two studies30,35, studies only examined Cauca-314	
sians, limiting the generalizability to other populations. All studies were performed in participants with a 315	
mean age >65 years and the time of follow-up was relatively short, ranging between 12 and 70.8 months 316	
(152.4 months in the Framingham Study,34 added in a sensitivity analysis). All but two studies 20,33 assessed 317	
thyroid function tests only at baseline, which is a limitation of most previously published large cohort stud-318	
ies on the risks of thyroid dysfunction54,55. Some participants with SCTD at baseline may have normalized 319	
to euthyroidism or progressed to overt thyroid disease over time. Regarding the elderly participants in the 320	
included studies, we cannot exclude a certain degree of overdiagnosis of SHypo due to the physiological 321	
rise of TSH towards upper limits during normal ageing.56 All these non-differential misclassification of 322	
thyroid status might bias the results towards no difference. The limited sensitivity of MMSE for detecting 323	
subtle changes in specific cognitive domains57 may further limit our ability to detect a possible decline in 324	
cognitive function. A meta-analysis of observational studies requires cautious interpretation of the results 325	
and potential biases, and confounding and heterogeneity must be carefully investigated.58,59 The quality of 326	
the incorporated studies was variable. We performed several sensitivity analyses to address differences be-327	
tween the studies, as recommended,58 although they should be interpreted with caution given the small 328	
number of studies. In study level meta-analysis, interpretation of subgroup data should be performed with 329	
caution. Because of the small amount of studies, no meaningful subgroup analysis could be performed. 330	
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There are multiple confounders for cognitive decline and dementia, the most important is age, others are 331	
depression/mood or cardiometabolic risk factors. All cohorts adjusted for age and several other confound-332	
ers, but there was heterogeneity in the choice of confounders, which may lead to residual confounding. Bias 333	
in the selection of included studies cannot be excluded. To limit selection bias, we conducted a detailed 334	
literature search in several electronic databases with broad inclusion. We performed graphical and statistical 335	
assessment to assess selective reporting, but these analyses were not very sensitive considering the small 336	
number of studies included.25,28 Although included cohorts enrolled community-dwelling adults in ambula-337	
tory visits, who are therefore less likely to have an acute disease, some participants with non-thyroidal ill-338	
ness may have been analyzed. Included studies addressed this problem differently: Two repeatedly meas-339	
ured thyroid values20,33, one assessed and adjusted for rT3 (reverse triiodothyronine)38, and others adjusted 340	
for comorbidities. We cannot exclude that some participants had nonthyroidal illness. 341	
What are the potential clinical and research implication of our findings? Our data suggest that SHyper might 342	
represent a potentially treatable risk factor for dementia. Given the relatively high prevalence of both SCTD 343	
and cognitive dysfunction in the aging population, even a modest increase of dementia incidence among 344	
individuals with SCTD might have public health implications. Data on benefit of SCTD treatment are 345	
scarce, therefore current guidelines do not recommend treatment for most adults with mild SCTD (serum 346	
TSH 0.1-0.45mU/l or 4.5-10.0mU/l).60,61 Large randomized controlled trials are required to assess the effi-347	
cacy of treatment in SCTD associated with dementia. For SHypo, the ongoing TRUST (Thyroid Hormone 348	
Replacement for Subclinical Hypothyroidism) trial (ClinicalTrials.gov: NCT01660126) will clarify this 349	
issue.62 350	
 351	
In summary, our systematic review and meta-analysis indicates that SHyper, but not SHypo, might be asso-352	
ciated with a modestly elevated risk of dementia. Neither SHyper nor SHypo were significantly associated 353	
with a faster decline in MMSE over time, as compared to euthyroidism. Available data were limited, and 354	
additional large, high-quality prospective cohort studies are needed.  355	
 356	
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